Item 8.01 Other Events

On August 12, 2021, CorMedix Inc. (the "Company"), entered into an At Market Issuance Sales Agreement (the "Sales Agreement") with Truist Securities, Inc. ("Truist Securities") and JMP Securities LLC ("JMP Securities"), as sales agents, pursuant to which the Company may sell, from time to time, an aggregate of up to $50,000,000 of its common stock, par value $0.001 per share (the "Shares").

The Shares may be issued and sold from time to time through or to Truist Securities and JMP Securities acting as sales agent or principal pursuant to the Company's shelf Registration Statement on Form S-3 (Reg. No. 333-249901). The Company has filed a prospectus supplement, on August 12, 2021, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with respect to the Shares. Sales of the Shares, if any, under this prospectus supplement may be made in transactions that are deemed to be "at the market offerings" pursuant to Rule 415 under the Securities Act of 1933, as amended.

The Company will pay the applicable sales agents a commission equal to 3% of the gross sales price per share for any Shares sold through such sales agents under the Sales Agreement. We have provided the sales agents with customary indemnification and contribution rights.

The foregoing description is qualified in its entirety by reference to the Sales Agreement, a copy of which is included as Exhibit 1.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits






(d) Exhibits



Exhibit No.   Description

1.1             Sales Agreement dated August 12, 2021

5.1             Opinion of Morgan, Lewis & Bockius LLP

© Edgar Online, source Glimpses